City investing com liquidating

The indemnification dispute stems from the issuance in 1981 of a surety bond by Continental for the benefit of General Development Corporation ("GDC"), then a subsidiary of City, a publicly traded, diversified holding company with billions of dollars in assets.

In response, Continental asserted a counterclaim, seeking to hold City Trust liable for indemnification.

I The proceedings in the Court of Chancery began with the filing of a declaratory judgment action by City Investing Company Liquidating Trust ("City Trust"), in which City Trust sought determination that it was not subject to suit by Continental Casualty Company ("Continental") for indemnification under a surety bond issued by Continental for the benefit of City Investing Company ("City"), a Delaware corporation.

We agree with the ruling of the Court of Chancery and, accordingly, affirm.

in a manner to conserve and protect the Trust Estate and to collect and distribute the beneficiaries proceeds.For the six months ended 6/30/01, revenues rose 42% to .7 million. Results reflect higher yield on investment securities and lower SG&A expenses as a percentage of sales.Terms of Service Company information Copyright Market Guide.The net cash estimate does not take into account AVGN’s AV411 assets and program, which could be worth considerably more, perhaps as much as M to M or between [[

in a manner to conserve and protect the Trust Estate and to collect and distribute the beneficiaries proceeds.

For the six months ended 6/30/01, revenues rose 42% to $2.7 million. Results reflect higher yield on investment securities and lower SG&A expenses as a percentage of sales.

Terms of Service Company information Copyright Market Guide.

The net cash estimate does not take into account AVGN’s AV411 assets and program, which could be worth considerably more, perhaps as much as $5M to $20M or between $0.15 or $0.60 per share.

The text of AVGN’s press release is set out below: In filings with the Securities and Exchange Commission on March 10, 11 and 18, 2009, Avigen disclosed that it had assessed the cash portion of the Medici Nova proposal described in those filings at approximately $0.91.

||

in a manner to conserve and protect the Trust Estate and to collect and distribute the beneficiaries proceeds.For the six months ended 6/30/01, revenues rose 42% to $2.7 million. Results reflect higher yield on investment securities and lower SG&A expenses as a percentage of sales.Terms of Service Company information Copyright Market Guide.The net cash estimate does not take into account AVGN’s AV411 assets and program, which could be worth considerably more, perhaps as much as $5M to $20M or between $0.15 or $0.60 per share.The text of AVGN’s press release is set out below: In filings with the Securities and Exchange Commission on March 10, 11 and 18, 2009, Avigen disclosed that it had assessed the cash portion of the Medici Nova proposal described in those filings at approximately $0.91.Historical chart data and daily updates provided by Commodity Systems, Inc. Data and information is provided for informational purposes only, and is not intended for trading purposes.

]].15 or [[

in a manner to conserve and protect the Trust Estate and to collect and distribute the beneficiaries proceeds.

For the six months ended 6/30/01, revenues rose 42% to $2.7 million. Results reflect higher yield on investment securities and lower SG&A expenses as a percentage of sales.

Terms of Service Company information Copyright Market Guide.

The net cash estimate does not take into account AVGN’s AV411 assets and program, which could be worth considerably more, perhaps as much as $5M to $20M or between $0.15 or $0.60 per share.

The text of AVGN’s press release is set out below: In filings with the Securities and Exchange Commission on March 10, 11 and 18, 2009, Avigen disclosed that it had assessed the cash portion of the Medici Nova proposal described in those filings at approximately $0.91.

||

in a manner to conserve and protect the Trust Estate and to collect and distribute the beneficiaries proceeds.For the six months ended 6/30/01, revenues rose 42% to $2.7 million. Results reflect higher yield on investment securities and lower SG&A expenses as a percentage of sales.Terms of Service Company information Copyright Market Guide.The net cash estimate does not take into account AVGN’s AV411 assets and program, which could be worth considerably more, perhaps as much as $5M to $20M or between $0.15 or $0.60 per share.The text of AVGN’s press release is set out below: In filings with the Securities and Exchange Commission on March 10, 11 and 18, 2009, Avigen disclosed that it had assessed the cash portion of the Medici Nova proposal described in those filings at approximately $0.91.Historical chart data and daily updates provided by Commodity Systems, Inc. Data and information is provided for informational purposes only, and is not intended for trading purposes.

]].60 per share.The text of AVGN’s press release is set out below: In filings with the Securities and Exchange Commission on March 10, 11 and 18, 2009, Avigen disclosed that it had assessed the cash portion of the Medici Nova proposal described in those filings at approximately [[

in a manner to conserve and protect the Trust Estate and to collect and distribute the beneficiaries proceeds.

For the six months ended 6/30/01, revenues rose 42% to $2.7 million. Results reflect higher yield on investment securities and lower SG&A expenses as a percentage of sales.

Terms of Service Company information Copyright Market Guide.

The net cash estimate does not take into account AVGN’s AV411 assets and program, which could be worth considerably more, perhaps as much as $5M to $20M or between $0.15 or $0.60 per share.

The text of AVGN’s press release is set out below: In filings with the Securities and Exchange Commission on March 10, 11 and 18, 2009, Avigen disclosed that it had assessed the cash portion of the Medici Nova proposal described in those filings at approximately $0.91.

||

in a manner to conserve and protect the Trust Estate and to collect and distribute the beneficiaries proceeds.For the six months ended 6/30/01, revenues rose 42% to $2.7 million. Results reflect higher yield on investment securities and lower SG&A expenses as a percentage of sales.Terms of Service Company information Copyright Market Guide.The net cash estimate does not take into account AVGN’s AV411 assets and program, which could be worth considerably more, perhaps as much as $5M to $20M or between $0.15 or $0.60 per share.The text of AVGN’s press release is set out below: In filings with the Securities and Exchange Commission on March 10, 11 and 18, 2009, Avigen disclosed that it had assessed the cash portion of the Medici Nova proposal described in those filings at approximately $0.91.Historical chart data and daily updates provided by Commodity Systems, Inc. Data and information is provided for informational purposes only, and is not intended for trading purposes.

]].91.Historical chart data and daily updates provided by Commodity Systems, Inc. Data and information is provided for informational purposes only, and is not intended for trading purposes.

434

Leave a Reply